Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Blood (2024) 143 (1): 21–31.

https://doi.org/10.1182/blood.2023020250

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Blood (2022) 139 (24): 3546–3557.

https://doi.org/10.1182/blood.2021014520

Published: 2022

Includes: Supplemental data

Journal Articles

Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis

Guru Subramanian Guru Murthy, Brent R. Logan, Stephanie Bo-Subait, Amer Beitingjaneh, Steven Devine, Nosha Farhadfar, Lohith Gowda, Shahrukh Hashmi, Hillard Lazarus, Sunita Nathan, Akshay Sharma, Jean A. Yared, Heather E. Stefanski, Michael A. Pulsipher, Jack W. Hsu, Galen E. Switzer, Sandhya R. Panch, Bronwen E. Shaw

Blood (2021) 138 (Supplement 1): 907.

https://doi.org/10.1182/blood-2021-150635

Published: 2021

Journal Articles

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Blood (2021) 138 (Supplement 1): 899.

https://doi.org/10.1182/blood-2021-149659

Published: 2021

Journal Articles

Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Affect Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic

Steven Devine, Michelle Kuxhausen, Stephen R. Spellman, Caitrin Fretham, Kwang Woo Ahn, Heather E. Stefanski, Jeffery J. Auletta, Brent R. Logan, Bronwen E. Shaw

Blood (2021) 138 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2021-151445

Published: 2021

Journal Articles

Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors

Sanghee Hong, Jing Zhao, Ji-Hyun Lee, Nosha Farhadfar, Jean C. Yi, Jaime M. Preussler, K. Scott Baker, Bronwen E. Shaw, Steven Devine, Karen Syrjala, John R. Wingard, Navneet S. Majhail, Zeina Al-Mansour

Blood (2021) 138 (Supplement 1): 4123.

https://doi.org/10.1182/blood-2021-145428

Published: 2021

Journal Articles

Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 - Report from World Marrow Donor Association

Blood (2021) 138 (Supplement 1): 3887.

https://doi.org/10.1182/blood-2021-150013

Published: 2021

Journal Articles

Neither COVID-19, Nor Cryopreservation, Prevented Allogeneic Product Infusion: A Report from the National Marrow Donor Program

Heather E. Stefanski, Jeni Newman, Jennifer Novakovich, Jacklyn Barten, Jason Oakes, Meghann Cody, Huy P Pham, Jeffery Auletta, John P. Miller, Steven Devine

Blood (2021) 138 (Supplement 1): 478.

https://doi.org/10.1182/blood-2021-152952

Published: 2021

Journal Articles

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant

Blood (2021) 138 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2021-153312

Published: 2021

Journal Articles

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

Basem M. William, John C. Reneau, Amanda Campbell, Anna Vilgelm, Michelle Watts, Lynn O'Donnell, Ying Huang, Catherine Chung, Marcos J.G. de Lima, Steven Devine, Sumithira Vasu, Dean Anthony Lee

Blood (2021) 138 (Supplement 1): 1388.

https://doi.org/10.1182/blood-2021-150543

Published: 2021

Journal Articles

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans

Rajshekhar Chakraborty, Lisa A. Rybicki, Jaime M. Preussler, Steven Devine, K. Scott Baker, Karen Syrjala, Jean C. Yi, Jennifer L Whitten, Bronwen E. Shaw, Navneet S. Majhail

Blood (2021) 138 (Supplement 1): 431.

https://doi.org/10.1182/blood-2021-149281

Published: 2021

Journal Articles

Distress, Health-Related Quality of Life (HQOL) and Confidence in Survivorship Information (CSI) in Older (≥60 Years) Hematopoietic Cell Transplant (HCT) Patients

Zeina Al-Mansour, Sanghee Hong, Nosha Farhadfar, Jing Zhao, Ji-Hyun Lee, Bronwen E. Shaw, Steven Devine, Jean C. Yi, Jaime M. Preussler, K. Scott Baker, Karen Syrjala, Navneet S. Majhail, John R. Wingard

Blood (2021) 138 (Supplement 1): 426.

https://doi.org/10.1182/blood-2021-151037

Published: 2021

Journal Articles

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Ephraim J. Fuchs, Paul V. O’Donnell, Mary Eapen, Brent Logan, Joseph H. Antin, Peter Dawson, Steven Devine, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, Eric Leifer, John M. Magenau, Joseph P. McGuirk, Lawrence E. Morris, Andrew R. Rezvani, Richard J. Jones, Claudio G. Brunstein

Blood (2021) 137 (3): 420–428.

https://doi.org/10.1182/blood.2020007535

Published: 2021

Includes: Supplemental data

Journal Articles

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Blood (2019) 134 (Supplement_1): 48.

https://doi.org/10.1182/blood-2019-125967

Published: 2019

Journal Articles

BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Sumithira Vasu, MDMBBS, Nelli Bejanyan, MD, Steven Devine, MD, Elizabeth Krakow, MDMSc, Elizabeth Krakow, MD, Brent Logan, PhD, Leo Luznik, MD, Brittany K Ragon, MD, Emma Barrett, MD, Joe Shan, MPH, BS, Richard E. Champlin, MD

Blood (2019) 134 (Supplement_1): 1955.

https://doi.org/10.1182/blood-2019-128005

Published: 2019

Journal Articles

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

John F. DiPersio, MD PhD, Jonathan Hoggatt, PhD, Steven Devine, MD, Lukasz Biernat, MD, Haley Howell, BS, BA, Veit Schmelmer, PhD, Jason R. Neale, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Kevin A. Goncalves, PhD, Glen D. Raffel, MD PhD, Patrick C. Falahee, PhD, Dwight M. Morrow, PhD, John C. Davis, Jr., MD MPH, MS

Blood (2019) 134 (Supplement_1): 1961.

https://doi.org/10.1182/blood-2019-127523

Published: 2019

Journal Articles

Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls

Stefan O. Ciurea, MD, Roland Bassett, Doris Soebbing, Gabriela Rondon, MD, Kai Cao, MS, MD, Amanda L. Olson, MD, Qaiser Bashir, MBBS, Elizabeth J. Shpall, MD, Steven Devine, Marcelo C. Pasquini, MD, Andrew St. Martin, MS, Dean Anthony Lee, MD PhD, Richard E Champlin

Blood (2019) 134 (Supplement_1): 700.

https://doi.org/10.1182/blood-2019-123936

Published: 2019

Journal Articles

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Blood (2019) 134 (Supplement_1): 4525.

https://doi.org/10.1182/blood-2019-129488

Published: 2019

Journal Articles

BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3- ITD + AML

Mark J. Levis, MD, Mehdi Hamadani, MD, Brent R. Logan, Matt Rosales, David Delgado, Erkut Bahceci, Steven Devine, MD, Mary M. Horowitz, Yi-Bin Chen

Blood (2019) 134 (Supplement_1): 4602.

https://doi.org/10.1182/blood-2019-124322

Published: 2019

Journal Articles

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 1311.

https://doi.org/10.1182/blood-2019-127418

Published: 2019

NARROW

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Affect Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic

Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors

Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 - Report from World Marrow Donor Association

Neither COVID-19, Nor Cryopreservation, Prevented Allogeneic Product Infusion: A Report from the National Marrow Donor Program

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans

Distress, Health-Related Quality of Life (HQOL) and Confidence in Survivorship Information (CSI) in Older (≥60 Years) Hematopoietic Cell Transplant (HCT) Patients

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3- ITD + AML

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only